714 related articles for article (PubMed ID: 34715816)
1. Survival improvement and prognosis for hepatocellular carcinoma: analysis of the SEER database.
Ding J; Wen Z
BMC Cancer; 2021 Oct; 21(1):1157. PubMed ID: 34715816
[TBL] [Abstract][Full Text] [Related]
2. Does fibrosis have an impact on survival of patients with hepatocellular carcinoma: evidence from the SEER database?
Liu H; Cen D; Yu Y; Wang Y; Liang X; Lin H; Cai X
BMC Cancer; 2018 Nov; 18(1):1125. PubMed ID: 30445928
[TBL] [Abstract][Full Text] [Related]
3. Racial/ethnic disparities in access to care and survival for patients with early-stage hepatocellular carcinoma.
Mathur AK; Osborne NH; Lynch RJ; Ghaferi AA; Dimick JB; Sonnenday CJ
Arch Surg; 2010 Dec; 145(12):1158-63. PubMed ID: 21173289
[TBL] [Abstract][Full Text] [Related]
4. Predictors of survival after resection of early hepatocellular carcinoma.
Nathan H; Schulick RD; Choti MA; Pawlik TM
Ann Surg; 2009 May; 249(5):799-805. PubMed ID: 19387322
[TBL] [Abstract][Full Text] [Related]
5. Prognostic factors for survival after hepatic resection of early hepatocellular carcinoma in HBV-related cirrhotic patients.
Zhu Q; Yuan B; Qiao GL; Yan JJ; Li Y; Duan R; Yan YQ
Clin Res Hepatol Gastroenterol; 2016 Sep; 40(4):418-27. PubMed ID: 26823044
[TBL] [Abstract][Full Text] [Related]
6. Impact of sex on the survival of patients with hepatocellular carcinoma: a Surveillance, Epidemiology, and End Results analysis.
Yang D; Hanna DL; Usher J; LoCoco J; Chaudhari P; Lenz HJ; Setiawan VW; El-Khoueiry A
Cancer; 2014 Dec; 120(23):3707-16. PubMed ID: 25081299
[TBL] [Abstract][Full Text] [Related]
7. Differences in the prognostic value of tumor size on hepatocellular cancer-specific survival stratified by gender in a SEER population-based study.
Zhang W; Jin K; Wang F; Zhangyuan G; Yu W; Liu Y; Zhang H; Zhang P; Sun B
United European Gastroenterol J; 2019 Aug; 7(7):933-941. PubMed ID: 31428418
[TBL] [Abstract][Full Text] [Related]
8. Clinical and prognostic implications of pretreatment albumin to C-reactive protein ratio in patients with hepatocellular carcinoma.
Wu MT; He SY; Chen SL; Li LF; He ZQ; Zhu YY; He X; Chen H
BMC Cancer; 2019 Jun; 19(1):538. PubMed ID: 31164099
[TBL] [Abstract][Full Text] [Related]
9. A SEER Database Analysis of the Survival Advantage of Transarterial Chemoembolization for Hepatocellular Carcinoma: An Underutilized Therapy.
Gray SH; White JA; Li P; Kilgore ML; Redden DT; Abdel Aal AK; Simpson HN; McGuire B; Eckhoff DE; Dubay DA
J Vasc Interv Radiol; 2017 Feb; 28(2):231-237.e2. PubMed ID: 27939085
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Clinical Features and Outcomes Between Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma in the United States.
Lee YT; Wang JJ; Luu M; Noureddin M; Nissen NN; Patel TC; Roberts LR; Singal AG; Gores GJ; Yang JD
Hepatology; 2021 Nov; 74(5):2622-2632. PubMed ID: 34114675
[TBL] [Abstract][Full Text] [Related]
11. Predictors of five-year survival among patients with hepatocellular carcinoma in the United States: an analysis of SEER-Medicare.
Zhang X; El-Serag HB; Thrift AP
Cancer Causes Control; 2021 Apr; 32(4):317-325. PubMed ID: 33394207
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant radiotherapy provided survival benefit compared to adjuvant radiotherapy for hepatocellular carcinoma.
Lin H; Li X; Liu Y; Hu Y
ANZ J Surg; 2018 Oct; 88(10):E718-E724. PubMed ID: 29399938
[TBL] [Abstract][Full Text] [Related]
13. Survival in Mesenchymal Chondrosarcoma Varies Based on Age and Tumor Location: A Survival Analysis of the SEER Database.
Schneiderman BA; Kliethermes SA; Nystrom LM
Clin Orthop Relat Res; 2017 Mar; 475(3):799-805. PubMed ID: 26975384
[TBL] [Abstract][Full Text] [Related]
14. Incorporation of alpha-fetoprotein(AFP) into subclassification of BCLC C stage hepatocellular carcinoma according to a 5-year survival analysis based on the SEER database.
Zhang N; Gu J; Yin L; Wu J; Du MY; Ding K; Huang T; He X
Oncotarget; 2016 Dec; 7(49):81389-81401. PubMed ID: 27835609
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of site-specific extra-hepatic disease in hepatocellular carcinoma: a SEER database analysis.
Oweira H; Petrausch U; Helbling D; Schmidt J; Mehrabi A; Schöb O; Giryes A; Abdel-Rahman O
Expert Rev Gastroenterol Hepatol; 2017 Jul; 11(7):695-701. PubMed ID: 28276812
[TBL] [Abstract][Full Text] [Related]
16. Relationship between Insurance Type at Diagnosis and Hepatocellular Carcinoma Survival.
Adler Jaffe S; Myers O; Meisner ALW; Wiggins CL; Hill DA; McDougall JA
Cancer Epidemiol Biomarkers Prev; 2020 Feb; 29(2):300-307. PubMed ID: 31796525
[TBL] [Abstract][Full Text] [Related]
17. Prognosis of Hepatocellular Carcinoma Among Cancer Survivors with Other Types of Primary Tumors.
Bian X; He X; Yang L; Wu W; Li L
Dig Dis Sci; 2020 Jul; 65(7):2140-2147. PubMed ID: 31673904
[TBL] [Abstract][Full Text] [Related]
18. The power of tumor sizes in predicting the survival of solitary hepatocellular carcinoma patients.
Yang A; Xiao W; Chen D; Wei X; Huang S; Lin Y; Zhang C; Lin J; Deng F; Wu C; He X
Cancer Med; 2018 Dec; 7(12):6040-6050. PubMed ID: 30430769
[TBL] [Abstract][Full Text] [Related]
19. Ablation for hepatocellular carcinoma: validating the 3-cm breakpoint.
Groeschl RT; Gamblin TC; Turaga KK
Ann Surg Oncol; 2013 Oct; 20(11):3591-5. PubMed ID: 23720072
[TBL] [Abstract][Full Text] [Related]
20. Survival and cost-effectiveness of sorafenib therapy in advanced hepatocellular carcinoma: An analysis of the SEER-Medicare database.
Parikh ND; Marshall VD; Singal AG; Nathan H; Lok AS; Balkrishnan R; Shahinian V
Hepatology; 2017 Jan; 65(1):122-133. PubMed ID: 27770556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
